Proline-rich peptides protective against S. pneumoniae

9,943,583

15/101214

December 02, 2014

The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.

VIROMETIX AG (Schlieren, CH); SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE (Basel, CH); UNIVERSITÄT BASEL (Basel, CH); UNIVERSITÄT ZÜRICH (Zürich, CH)

UNIVERSITÄT ZÜRICH (Zürich, CH), SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE (Basel, CH), VIROMETIX AG (Schlieren, CH)

1. The lipopeptide building block consisting of (1) a peptide chain comprising a parallel coiled-coil domain which, as a self-standing lipid-free peptide, forms a parallel dimeric, trimeric or higher order oligomeric helical bundle, (2) a proline-rich peptide antigen comprising at least one negatively and at least one positively charged amino acid, and wherein at least 15% of the amino acids are proline, optionally linked to a further antigen, and wherein said proline-rich peptide antigen consists of 8-80 amino acids, and wherein said proline-rich peptide antigen comprises any one of sequences selected from the group consisting of SEQ ID NO:27 to 112 or comprises any one of sequences selected from the group consisting of SEQ ID NO:27 to 112 wherein one, two or three amino acids are replaced by other amino acids; and (3) a lipid moiety comprising two or three long hydrocarbyl chains, wherein the peptide chain, the proline-rich peptide antigen and the lipid moiety are covalently linked, either directly or through a linker.

2. The lipopeptide building block according to claim 1 wherein the peptide chain comprises between 21 and 200 amino acid residues.

3. The lipopeptide building block according to claim 1 wherein the peptide chain comprises a coiled-coil domain consisting of three to eight heptad motifs.

4. The lipopeptide building block according to claim 3 wherein in the coiled-coil domain positions a and d in each heptad motif (abcdefg) comprise alpha-amino acids with small to medium-sized hydrophobic side chains and/or aromatic or heteroaromatic side chains, in zero, one or two of all the a and d positions an amino acid with a polar non-charged residue and in zero or one of all the a and d positions an amino acid with a polar cationic residue or an acylated derivative thereof, or with a polar anionic residue, or glycine.

5. The lipopeptide building block according to claim 4 wherein the alpha-amino acids with small to medium-sized hydrophobic side chain are alanine, isoleucine, leucine, methionine and valine; the alpha-amino acids with aromatic or heteroaromatic side chain are phenylalanine, tyrosine, tryptophan and histidine; the alpha-amino acids with polar non-charged residue are asparagine, cysteine, glutamine, serine and threonine; the alpha-amino acids with polar cationic residue are arginine, lysine and histidine; and the alpha-amino acids with polar anionic residue are aspartic acid and glutamic acid.

6. The lipopeptide building block according to claim 1 wherein the proline-rich peptide antigen comprises at least one glutamic acid residue and at least one lysine or arginine residue.

7. The lipopeptide building block according to claim 1 wherein the proline-rich peptide antigen is an amino acid sequence comprising 50% or more of one or more amino acid sequences from proteins of Streptococci and/or Staphylococci.

8. The lipopeptide building block according to claim 1 wherein the proline-rich peptide antigen is an amino acid sequence comprising 50% or more of one or more amino acid sequences from proteins PspA and/or PspC.

9. The lipopeptide building block according to claim 1 wherein the lipid moiety is one of types Z 1 to Z 8 [chemical expression included] wherein R 1 and R 2 are long hydrocarbyl or long hydrocarbyl-C═O and Y is H or COOH, [chemical expression included] wherein R 1 , R 2 and R 3 are long hydrocarbyl or long hydrocarbyl-C═O or R 1 and R 2 are long hydrocarbyl or long hydrocarbyl-C═O and R 3 is H or acetyl or lower alkyl-C═O, [chemical expression included] wherein R 1 and R 2 are long hydrocarbyl or long hydrocarbyl-C═O and n is 1, 2, 3 or 4, or [chemical expression included] wherein R 1 and R 2 are long hydrocarbyl, X is 0 or NH, and n is 1, 2, 3 or 4, or [chemical expression included] wherein R 1 and R 2 are long hydrocarbyl, and wherein long hydrocarbyl is straight or branched alkyl or alkenyl consisting of between 8 and 25 carbon atoms and optionally one, two or three double bonds in the chain.

10. The lipopeptide building block according to claim 9 wherein the lipid moiety is di-palmitoyl-S-glycerylcysteinyl of formula Z 3 , wherein R 1 and R 2 are palmitoyl and R 3 is H or acetyl.

11. The lipopeptide building block according to claim 1 wherein the peptide chain comprising a parallel coiled coil is linked at one end to the PR peptide antigen and at the other end to the lipid moiety.

12. The lipopeptide building block according to claim 11 wherein the peptide chain PC is covalently linked to the lipid moiety LM at or near one terminus of the peptide chain either directly as in LM-PC  (1) or via a linker (L) as in LM-L-PC  (2) wherein linker L is selected from [chemical expression included] [chemical expression included] wherein X is O or NH, m is between 1 and 45 and n is between 1 and 45.

13. Synthetic virus-like particles consisting of helical lipopeptide bundles comprising two, three, four, five, six or seven lipopeptide building blocks according to claim 1 .

14. A vaccine comprising the synthetic virus-like particle according to claim 13 .

15. A method of vaccination against a disease caused by Gram-negative bacteria wherein an immunogenically effective amount of the synthetic virus-like particle according to claim 13 is administered to a patient in need thereof.

16. The lipopeptide building block according to claim 8 wherein said one or more amino acid sequences from proteins PspA and/or PspC are amino acid sequences located after the C-terminal end of the helical region and before the non-proline block of said proteins PspA or PspC.

17. The lipopeptide building block according to claim 1 wherein said proline-rich peptide antigen consists of any one of sequences selected from the group consisting of SEQ ID NO:27 to 112.

18. The lipopeptide building block according to claim 1 wherein said proline-rich peptide antigen consists of any one of sequences selected from the group consisting of SEQ ID NO:27 to 112 wherein one, two or three amino acids are replaced by other amino acids.

19. The lipopeptide building block according to claim 1 wherein said proline-rich peptide antigen consists of any one of sequences selected from the group consisting of SEQ ID NO:27 to 29 or 86.

4663160 May 1987 Tsay
6592876 July 2003 Briles
1996/40290 December 1992
2008/068017 June 2008
WO2008/068017 June 2008
2012/100233 July 2012

Betts et al. Amino Acid Properties and Consequences of Substitutions. Chapter 14. Bioinformatics for Geneticists. 2003. pp. 289-316. cited by examiner
Beall et al. Pneumococcal pspA Sequence Types of Prevalent Multiresistant Pneumococcal Strains in the United States and of Internationally Disseminated Clones. J Clin Microbiology, 2000. vol. 38, No. 10, pp. 3663-3669. cited by examiner
Berndt et al., “Synthetic Lipidation of Peptides and Amino Acids: Monolayer Structure and Properties,” Journal of the American Chemical Society 117(37):9515-9522 (1995). cited by applicant
Boato et al., “Synthetic Virus-Like Particles from Self-Assembling Coiled-Coil Lipopeptides and Their Use in Antigen Display to the Immune System,” Angewandte Chemie 119:9173-9176 (2007). cited by applicant
Daniels et al., “The Proline-Rich Region of Pneumococcal Surface Proteins A and C Contains Surface-Accessible Epitopes Common to All Pneumococci and Elicits Antibody-Mediated Protection against Sepsis,” Infection and Immunity 78(5):2163-2172 (2010). cited by applicant
Ghasparian et al., “Engineered Synthetic Virus-Like Particles and Their Use in Vaccine Delivery,” ChemBioChem 12(1):100-109 (2011). cited by applicant
Jedrzejas et al., “Characterization of Selected Strains of Pneumococcal Surface Protein A,” Journal of Biological Chemistry 276(35):33121-33128 (2001). cited by applicant
Langermann et al., “Protective Humoral Response Against Pneumococcal Infection in Mice Elicited by Recombinant Bacille Calmette-Guerin Vaccines Expressing Pneumococcal Surface Protein A,” Journal of Experimental Medicine 180(6):2277-2286 (1994). cited by applicant
Melin et al., “Development of cross-reactive antibodies to the proline-rich region of pneumococcal surface protein A in children,” Vaccine 30(50):7157-7160 (2012). cited by applicant
Riedel et al., “Synthetic Virus-Like Particles and Conformationally Constrained Peptidomimetics in Vaccine Design,” ChemBioChem 12(18):2829-2836 (2011). cited by applicant
Sharma et al., “Synthetic Virus-Like Particles Target Dendritic Cell Lipid Rafts for Rapid Endocytosis Primarily but Not Exclusively by Macropinocytosis,” PLoS One 7(8):e43248 (2012). cited by applicant
Woolfson, et al., “The Design of Coiled-Coil Structures and Assemblies,” Advances in Protein Chemistry 70:79-112 (2005). cited by applicant
Yother et al., “Structural Properties and Evolutionary Relationships of PspA, a Surface Protein of Streptococcus pneumoniae, as Revealed by Sequence Analysis,” Journal of Bacteriology 174(2):601-609 (1992). cited by applicant
International Search Report for PCT/EP2014/076313, dated Feb. 17, 2015. cited by applicant

edspgr.09943583